MannKind Corp (STU:NNFN)
€ 3.424 +0.12 (+3.66%) Market Cap: 1.06 Bil Enterprise Value: 947.18 Mil PE Ratio: 41.00 PB Ratio: 0 GF Score: 67/100
Back to the Transcripts List

Q4 2024 MannKind Corp Earnings Call Transcript

Feb 26, 2025 / 09:30 PM GMT
Release Date Price: €5.14 (-3.60%)

Key Points

Positve
  • MannKind Corp (MNKD) reported a 31% increase in fourth-quarter revenues, reaching $77 million, and a 43% increase for the full year, totaling $286 million.
  • The company successfully reduced its debt principal by $236 million in 2024, ending the year with a strong cash position of $203 million.
  • MannKind Corp (MNKD) achieved record revenues in its endocrine business unit, with Q4 revenue of $23 million and full-year revenue of $82 million.
  • The company has two FDA-approved products on its technosphere platform and is advancing its pipeline with promising candidates like clofazimine inhalation suspension and techev DPI.
  • MannKind Corp (MNKD) announced a collaboration with Anasstar, enabling the promotion of Maximi through its US sales force, which is expected to enhance its pediatric footprint.
Negative
  • The company faces challenges in launching its pediatric indication, with approval not expected until early 2026.
  • Vigo net revenue decreased by 4% over the prior year, and the salesforce is no longer actively promoting the product.
  • Despite the progress, MannKind Corp (MNKD) anticipates potential delays in its India launch due to packaging and shipping issues.
  • The company is still working on expanding its institutional selling capabilities, which is crucial for its future growth in the pediatric market.
  • MannKind Corp (MNKD) acknowledges the need for significant investments in its FRSA business, which could impact margins in the near term.


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

MNKD.OQ - MannKind Corp
Q4 2024 MannKind Corp Earnings Call
Feb 26, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome to the Mankind Corporation 4th quarter and year 2024 financial results earnings call. As a reminder, this call is being recorded on February 26, 2025 and will be available for playback on the Mankind Corporation website shortly after the conclusion of this call and available for approximately 90 days.

This call will contain forward-looking statements. Such forward-looking statements are subject to risk and uncertainty which can cause actual risk to differ materially from these stated expectations. For further information on the company's risk factors, please see the 10K report filed with the Securities and Exchange Commission this afternoon, the earnings release, and the slides prepared for this presentation.
Already have an account? Log in
Get the full story
Start 7-Day Free Trial
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2025 GuruFocus.com, LLC. All Rights Reserved.